Highlander Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Highlander Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-120	Closed	-$16K	–	789
2016 Q4	$16K	Sell	120 -280	-70%	-$49.7K	0.01%	545
2016 Q3	$80K	Sell	400 -250	-38%	-$43.1K	0.07%	275
2016 Q2	$84K	Hold	650	–	–	0.08%	270
2016 Q1	$61K	Hold	650	–	–	0.06%	317
2015 Q4	$132K	Sell	650 -1,425	-69%	-$255K	0.12%	196
2015 Q3	$301K	Buy	2,075 +150	+8%	+$27.5K	0.29%	97
2015 Q2	$409K	Buy	1,925 +1,325	+221%	+$325K	0.37%	72
2015 Q1	$139K	Sell	600 -50	-8%	-$12.1K	0.12%	197
2014 Q4	$150K	Buy	+650	New	+$139K	0.13%	187

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highlander Capital Management's BLCM Position: Q1 2017 in Review

Highlander Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2017, closing a stake of 120 shares — an estimated $16K sold.

Highlander Capital Management first reported a position in BLCM in Q4 2014 and held it in 9 quarters. The position peaked at $409K in Q2 2015. 96 funds tracked by Wall St. Rank hold BLCM as of Q1 2017.

Highlander Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Highlander Capital Management sold 120 Bellicum Pharmaceuticals, Inc. shares in Q1 2017, an estimated $16K.
Highlander Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
Highlander Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $409K in Q2 2015.
96 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2017.

Based on Highlander Capital Management's 13F filing for Q1 2017, filed 15 May 2017.